Celecoxib increases retinoid sensitivity in human colon cancer cell lines

Cellular and Molecular Biology Letters

Volumn 15, Issue 3, 2010, Pages 440-450

  Liu, Jian Pei ^a   Wei, Hong Bo ^a   Zheng, Zong Heng ^a   Guo, Wei Ping ^a   Fang, Jia Feng ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Celecoxib; Colonic neoplasm; Retinoic acid; Sensitivity

Indexed keywords

CELECOXIB; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; RETINOIC ACID; RETINOIC ACID RECEPTOR BETA; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN E2; PYRAZOLE DERIVATIVE; RETINOIC ACID RECEPTOR; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL STRAIN HT29; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; COLON TUMOR; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; HT29 CELLS; HUMANS; NITROBENZENES; PYRAZOLES; RECEPTORS, RETINOIC ACID; SULFONAMIDES; TRETINOIN;

EID: 77956937273     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-010-0016-2     Document Type: Article

References (26)

1. Weitz, J., Koch, M., Debus, J., Hohler, T., Galle, P. R. and Buchler, M. W. Colorectal cancer. Lancet365 (2005) 153-165.
2. Sabharwal, A. and Kerr, D. Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Rev. Anticancer Ther. 7 (2007) 477-487.
3. Gudas, L. J., Sporn, M. B. and Roberts, A. B. Cellular biology and biochemistry of the retinoids. in: The retinoids: Biology, Chemistry, and Medicine (Sporn, M. B., Roberts, A. B. and Goodman, D. S., Eds.), 2nd edition, Raven Press, New York, 1994, 443-520.
4. Xu, X. C. Tumor-suppressive activity of retinoic acid receptor-beta in cancer. Cancer Lett. 253 (2007) 14-24.
5. Lee, M. O., Han, S. Y., Jiang, S., Park, J. H. and Kim, S. J. Differential effects of retinoic acid on growth and apoptosis in human colon cancer cell lines associated with the induction of retinoic acid receptor beta. Biochem. Pharmacol. 59 (2000) 485-496.
6. van Zandwijk, N., Dalesio, O., Pastorino, U., de Vries, N. and van Tinteren, H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the EUropean Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J. Natl. Cancer Inst. 92 (2000) 977-986.
7. Khuri, F. R., Lee, J. J., Lippman, S. M., Kim, E. S., Cooper, J. S., Benner, S. E., Winn, R., Pajak, T. F., Williams, B., Shenouda, G., Hodson, I., Fu, K., Shin, D. M., Vokes, E. E., Feng, L., Goepfert, H. and Hong, W. K. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J. Natl. Cancer Inst. 98 (2006) 441-450.
8. Koki, A. T., Leahy, K. M. and Masferrer, J. L. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Expert Opin. Investig. Drugs. 8 (1999) 1623-1638.
9. Rostom, A., Dube, C., Lewin, G., Tsertsvadze, A., Barrowman, N., Code, C., Sampson, M. and Moher, D. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U. S. Preventive Services Task Force. Ann. Intern. Med. 146 (2007) 376-389.
10. Simeone, A. M., Li, Y. J., Broemeling, L. D., Johnson, M. M., Tuna, M. and Tari, A. M. Cyclooxygenase-2 is essential for HER2/neu to suppress N- (4-hydroxyphenyl)retinamide apoptotic effects in breast cancer cells. Cancer Res. 64 (2004) 1224-1228.
11. Tari, A. M., Simeone, A. M., Li, Y. J., Gutierrez-Puente, Y., Lai, S. and Symmans, W. F. Cyclooxygenase-2 protein reduces tamoxifen and N-(4-hydroxyphenyl)retinamide inhibitory effects in breast cancer cells. Lab. Invest. 85 (2005) 1357-1367.
12. Schroeder, C. P., Kadara, H., Lotan, D., Woo, J. K., Lee, H. Y., Hong, W. K. and Lotan, R. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells. Cancer Res. 66 (2006) 9762-9770.
13. Li, M., Song, S., Lippman, S. M., Zhang, X. K., Liu, X., Lotan, R. and Xu, X. C. Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells. Oncogene21 (2002) 411-418.
14. Song, S., Lippman, S. M., Zou, Y., Ye, X., Ajani, J. A. and Xu, X. C. Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression. Oncogene24 (2005) 8268-8276.
15. Delage, B., Bairras, C., Buaud, B., Pallet, V. and Cassand, P. A high-fat diet generates alterations in nuclear receptor expression: prevention by vitamin A and links with cyclooxygenase-2 and beta-catenin. Int. J. Cancer. 116 (2005) 839-846.
16. Mernitz, H., Smith, D. E., Zhu, A. X. and Wang, X. D. 9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett. 244 (2006) 101-108.
17. Freemantle, S. J., Spinella, M. J. and Dmitrovsky, E. Retinoids in cancer therapy and chemoprevention: promise meets resistance. Oncogene22 (2003) 7305-7315.
18. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S. and Kawai, S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531 (2002) 278-284.
19. Williams, C. S., Watson, A. J., Sheng, H., Helou, R., Shao, J. and DuBois, R. N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045-6051.
20. Niederberger, E., Tegeder, I., Vetter, G., Schmidtko, A., Schmidt, H., Euchenhofer, C., Brautigam, L., Grosch, S. and Geisslinger, G. Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NFkappaB. FASEB J. 15 (2001) 1622-1624.
21. Zrieki, A., Farinotti, R. and Buyse, M. Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm. Res. 25 (2008) 1991-2001.
22. Sulova, Z., Macejova, D., Seres, M., Sedlak, J., Brtko, J. and Breier, A. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol. In Vitro22 (2008) 96-105.
23. Soprano, D. R., Qin, P. and Soprano, K. J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 24 (2004) 201-221.
24. Grosch, S., Maier, T. J., Schiffmann, S. and Geisslinger, G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747.
25. Maier, T. J., Schilling, K., Schmidt, R., Geisslinger, G. and Grosch, S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67 (2004) 1469-1478.
26. Lefebvre, B., Brand, C., Flajollet, S. and Lefebvre, P. Down-regulation of the tumor suppressor gene retinoic acid receptor beta2 through the phosphoinositide 3-kinase/Akt signaling pathway. Mol. Endocrinol. 20 (2006) 2109-2121.